Physiomics plc announced that it has been awarded a substantial new contract by an existing large pharma client. The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178,000 and it is anticipated that it will be completed over the course of the next six months.